In June 2018, the company described its foundation of new gene therapy companies as an expansion of its global leadership in the field.

The fund founded SwanBio and Orbit Biomedical to take its gene therapy group to five companies.

SwanBio’s focus on the central nervous system means that Syncona’s portfolio companies now cover every tissue compartment where gene therapy has proof of concept – retina, liver and CNS.